Tag Archives: AI drug discovery

October 6, 2020
In The News

Atomwise announced today $2.3M in grant funding for AI-based discovery of antimalarial and anti-tuberculosis therapies.

Read Article
October 6, 2020
FeaturedPress Release

The $2.3M in grant funding from the Bill & Melinda Gates Foundation will support the development of multiple global health programs to advance novel antimalarial and anti-tuberculosis small molecule therapies in collaboration with the foundation’s global network SAN FRANCISCO, CA — October 6th, 2020 — Atomwise, the leader in using artificial intelligence (AI) for small […]

Read Article
October 2, 2020
In The News

When MIT mathematician Jim Simmons founded Renaissance Technologies in 1988, it was unfathomable that computers driven by algorithms might outperform top Wall Street fund managers. Today, after a more than thirty year average return of 66% per annum, the Renaissance model of applying machine learning techniques to invest in a manner that is automated, dispassionate […]

Read Article
September 23, 2020
In The News

[Hemophilia News Today] Atomwise, a company that specializes in using artificial intelligence (AI) to develop small molecule medicines, will partner with GC Pharma to discover new ways of treating people with hemophilia. 

Read Article
September 11, 2020
In The News

[Korea Biomedical Review] GC said that it has partnered with Atomwise, a U.S. artificial intelligence-based drug development firm, to discover a new treatment candidate for hemophilia.

Read Article
September 8, 2020
FeaturedPress Release

The partnership will develop new drug programs that advance GC Pharma’s global leadership in hemophilia and additional disease areas SAN FRANCISCO & YONGIN, South Korea–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross […]

Read Article